About the Company
amicus therapeutics is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. we have a unique set of platform technologies and medicines in development for patients living with the lysosomal storage disorders fabry disease and pompe disease and we are committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for these and other rare diseases. the needs of patients in the rare disease community are at the center of our inventive science, our commercial organization, and our clinical programs. our goal throughout all levels of the organization is to make a meaningful difference in the lives of these patients and their caregivers. several opportunities are available to join our team as we build a leading global biotechnology company focused on rare metabolic diseases. our amicus footprint spans 27 countries including our g
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $FOLD News
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
Last week saw the newest full-year earnings release from Amicus Therapeutics, Inc. (NASDAQ:FOLD), an important milestone in ...
Amicus' (FOLD) Q4 Earnings Beat, Revenues Meet Estimates
Amicus Therapeutics, Inc. FOLD reported fourth-quarter 2023 adjusted earnings of 1 cent per share against the Zacks Consensus ...
Amicus Therapeutics Stock Sees RS Rating Improve To 74
Amicus Therapeutics stock earns the No. 59 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, Neurocrine Biosciences and Alkermes are among the top 5 highly ...
Amicus’s Growth Trajectory Reinforces Buy Rating Amid Strong Product Prospects and Revenue Milestones
J.P. Morgan analyst Anupam Rama has maintained their bullish stance on FOLD stock, giving a Buy rating on February 28. Anupam Rama’s ...
Director Margaret Mcglynn Sells 15,000 Shares of Amicus Therapeutics Inc (FOLD)
Director Margaret Mcglynn has sold 15,000 shares of Amicus Therapeutics Inc (NASDAQ:FOLD) on March 5, 2024, according to a ...
Alkermes Wins Quick Reversal From FDA on Antidepressant Drug
Two weeks ago, the agency told Alkermes it needed more trials for antidepressant drug candidate ALKS-5461. The agency, ...
FOLD Jul 2024 12.000 call
Director Margaret Mcglynn has sold 15,000 shares of Amicus Therapeutics Inc (NASDAQ:FOLD) on March 5, 2024, according to a recent SEC Filing.
Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier
Voyager Therapeutics investors need to be patient as the biotech targets hard to treat Alzheimer's and Parkinson's. Read why ...
Biotech Stock News Bite - Elicio Therapeutics, Inc. (Nasdaq: ELTX) Rises on Funding News
Investorideas.com ( Biotech Stock News Bites - Elicio Therapeutics, Inc. (Nasdaq: ELTX), a clinical-stage biotechnology ...
The Latest Analyst Ratings For Alignment Healthcare
Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Alignment Healthcare ...
Veeva Systems Inc Class A
View Veeva Systems Inc Class A VEEV stock quote prices, financial information, real-time forecasts, and company news from CNN.
Review Bombing Case: The Amicus Curiae recommends a 48-hour window for reviews
The Kerala High Court, with the help of the Amicus Curiae, is considering guidelines to regulate movie reviews by social ...
Loading the latest forecasts...